Clot management device market growing

Some segments stronger than others

The U.S. market for clot management devices is on the rise, a mix of relatively mature and dynamic, fast-growing segments, according to a new report from Millennium Research Group (MRG).

While the device market's average annual growth through 2017 will be 4.1 percent, the study shows, several more dynamic segments, such as endovascular treatments for deep vein thrombosis (DVT) and acute ischemic stroke (AIS) show much greater growth potential.

DVT causes some 600,000 hospitalizations, and the resulting pulmonary embolisms cause more than 100,000 deaths annually in the U.S. Increasing physician awareness of the endovascular treatment options for DVT and for preventing pulmonary embolism will boost procedure volume growth of pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) devices, according to Millennium.

Growth will be limited somewhat by the need for specific training to maximize effectiveness and safety, however. Clinical fellowships and training workshops provided by device manufacturers will be key to promoting the next-generation devices recently introduced.

In particular, the neurovascular embolectomy device segment, which includes devices used in the interventional treatment of AIS, has significant growth potential, the study shows. Recent technological innovation has improved the functional benefits of these devices for AIS treatment.

Millennium points to Covidien's Solitaire FR revascularization device and Stryker's Trevo Pro and Trevo ProVue devices, which were released in 2012. These premium-priced devices not only achieve significantly higher rates of revascularization than the first-to-market Merci Retriever device, but also offer significantly improved ease-of-use for physicians, researchers say.

“The most significant limiting factor to growth in this market is the lack of clinical data demonstrating the benefits of clot management procedures as compared to systemic thrombolysis,” said MRG Analyst Tony Su.



"Recent clinical trials did not find better outcomes from including thrombectomy," he said. "Device manufacturers have begun funding prospective, randomized clinical trials with the aim of providing the level of clinical evidence that is necessary to justify AIS patient referrals to neurovascular embolectomy."

 

[See also: Medical device industry feeling ill over SCOTUS healthcare ruling]